Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

Table 1 Clinical characteristics of the pediatric Crohn’s disease patients included in the study (n = 53) n (%)

Clinical characteristics of the pediatric Crohn’s disease
Males	36 (68)
Age years (median, IQR)	14.9 (11.9-16.0)
Age at diagnosis years (median, IQR)	10.9 (8.3-13.1)
Duration of disease years (median, IQR)	3.0 (1.3-5.1)
Concomitant immunosuppressant
Azathioprine	27 (51)
Methotrexate	19 (36)
None	7 (13)
Previous IBD related surgery
Perianal surgery	1 (2)
Resectional surgery	6 (11)
Crohn’s disease: Age at diagnosis (Paris classification)
A1a: 0-< 10 yr	20 (38)
A1b: 10-< 17 yr	33 (62)
Crohn’s disease: Location (Paris classification)
L1	5 (9)
L2	22 (42)
L3	26 (49)
L4	35 (66)
Crohn’s disease: Behaviour (Paris classification)
B1: non-stricturing, non-penetrating	31 (59)
B2: stricturing	12 (23)
B3: penetrating	7 (13)
B2B3: penetrating and structuring	3 (5)
P: Perianal disease	17 (32)
Crohn’s disease: Growth impairment (Paris classification)
Evidence of growth delay	0 (0)
Infliximab dosing
Interval between infliximab doses (wk), mean (range)	7 (4-8)
Mean dose (mg/kg)	6.8

IQR: Interquartile range; IBD: inflammatory bowel disease.